INOVIQ Exosome Diagnostic Solutions

Breast cancer monitoring study | Study 1 design For personal use only Study 1: To determine whether SubB2M/CA15-3 is equally expressing in women with different subtypes of breast cancer Pre-treatment serum Hormone receptor breast cancer (n=50) Her2 positive breast cancer (n=50) Triple Negative breast cancer (n=50) Age matched controls (n=65) SubB2M/CA15-3 test comparison between types of BC comparison between test IVD CA15-3 test 11 INOVIQ

View entire presentation